CYTEC INDS INC (CYT)
(Delayed Data from NYSE)
$75.17 USD
+0.02 (0.03%)
Updated Dec 8, 2015 04:01 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Cyteir Therapeutics, Inc. [CYT]
Reports for Purchase
Showing records 21 - 40 ( 156 total )
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Financials; CYT-0851 RP2D Picked; Study Expands
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; CYT-0851 Study Broadening on Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Initiating with OUTPERFORM and $40 PT; A Cut Above
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cyteir Therapeutics, Inc.
Industry: Medical - Drugs
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Weekly Arb Spread
Provider: G.RESEARCH, LLC
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Specialty Chemicals Leading Indicators Through September 2015
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Flight Has Landed; Downgrading to Sector Weight as CYT Is Above Our Price Target Given Solvay Deal
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
CYT Finds the Golden Road, Sells to Solvay for $75.25/share
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Specialty Chemicals Leading Indicators Through June 2015
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Strong Growth Potential Is Built to Last Due to a High Quality Portfolio, Attractive on Weakness
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
A Little Turbulence, 2Q15 Misses, 2015 EPS Guidance Sustained
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Specialty Chemicals Leading Indicators Through May 2015
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M
Company: Cyteir Therapeutics, Inc.
Industry: Chemical - Diversified
Specialty Chemicals Leading Indicators Through April 2015
Provider: KEYBANC CAPITAL MARKETS
Analyst: SISON M